Drugs / rhPSMA-7.3 (18F)
rhPSMA-7.3 (18F)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03995888 | Jun 2019 → Apr 2020 | prostate cancer | Blue Earth Diagnostics | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05678322 | Jan 2023 → May 2025 overdue | prostate cancer | NYU Langone Health | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04186845 | May 2020 → Apr 2021 | prostate cancer | Blue Earth Diagnostics | Completed | No outcome recorded |
Press releases naming this drug 19 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhPSMA-7.3 (18F) | “rhPSMA-7.3 (18F) will be administered intravenously as a single-dose injection.” NCT05678322 ↗ |
| Known as | 18F-flotufolastat | “18F-rhPSMA-7.3 (18F-flotufolastat) is a high-affinity prostate-specific membrane antigen-targeted diagnostic radiopharmaceutical for PET imaging in patients with prostate cancer.” PMID 38782456 ↗ Jul 2024 |
| Known as | 18F-rhPSMA-7.3 | “18F-rhPSMA-7.3 (18F-flotufolastat) is a high-affinity prostate-specific membrane antigen-targeted diagnostic radiopharmaceutical for PET imaging in patients with prostate cancer.” PMID 38782456 ↗ Jul 20241“a novel theranostic PET radiopharmaceutical, 18F-rhPSMA-7.3, to optimise its use for imaging of prostate cancer” PMID 33846844 ↗ Apr 2021 |
| Modality | Diagnostic / imaging agent | “very promising PET radiopharmaceutical for diagnostic imaging of prostate cancer” PMID 33846844 ↗ Apr 2021 |
| Route | Intravenous | “Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan” NCT03995888 ↗ |